NRSN (NeuroSense Therapeutics) Current Accrued Expense : $0.76 Mil (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is NeuroSense Therapeutics Current Accrued Expense?

NeuroSense Therapeutics's Current Accrued Expense for the quarter that ended in Dec. 2024 was $0.76 Mil.

NeuroSense Therapeutics's quarterly Current Accrued Expense stayed the same from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.00 Mil) but then increased from Sep. 2024 ($0.00 Mil) to Dec. 2024 ($0.76 Mil).

NeuroSense Therapeutics's annual Current Accrued Expense increased from Dec. 2022 ($0.79 Mil) to Dec. 2023 ($1.93 Mil) but then declined from Dec. 2023 ($1.93 Mil) to Dec. 2024 ($0.76 Mil).

NeuroSense Therapeutics Current Accrued Expense Historical Data

The historical data trend for NeuroSense Therapeutics's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeuroSense Therapeutics Current Accrued Expense Chart

NeuroSense Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Current Accrued Expense

Get a 7-Day Free Trial

0.07

0.56

0.79

1.93

0.76

NeuroSense Therapeutics Quarterly Data
	Dec19	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Current Accrued Expense	Get a 7-Day Free Trial													1.93	-	-	-	0.76

NeuroSense Therapeutics Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

NeuroSense Therapeutics Current Accrued Expense Related Terms

Thank you for viewing the detailed overview of NeuroSense Therapeutics's Current Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

NeuroSense Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NeuroSense Therapeutics Ltd (NAS:NRSN) » Definitions » Current Accrued Expense

Comparable Companies

Traded in Other Exchanges

H1Z:Germany

Address

11 HaMenofim Street, Building B, Herzliya, ISR, 4672562

Website

https://www.neurosense-tx.com

NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.